
JeeSuk Chang/X
Feb 24, 2025, 14:08
JeeSuk Chang: The 2nd analysis of SABR-5
JeeSuk Chang, Radiation Oncologist at Yonsei Cancer Center, shared an article by Sarah Baker, et al. on X:
“Check out the 2nd analysis of SABR-5!
Honored to be part of this team.
Ultracentral tumors = distant/widespread mets PFS/OS (despite similar LC).
Re-emphasizing the importance of risk-adapted dosing and strict OAR constraints.”
The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.
Authors: Sarah Baker, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 24, 2025, 14:08
Feb 24, 2025, 14:00
Feb 24, 2025, 13:59
Feb 24, 2025, 13:47
Feb 24, 2025, 13:31
Feb 24, 2025, 10:10
Feb 24, 2025, 09:47
Feb 24, 2025, 09:42